Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas
Yoko Fujita, Luis Nunez-Rubiano, Antonio Dono, et al.
Journal of Neuro-Oncology (2022) Vol. 159, Iss. 2, pp. 261-270
Open Access | Times Cited: 22

Showing 22 citing articles:

IDH inhibition in gliomas: from preclinical models to clinical trials
Roberta Rudà, Craig Horbinski, Martin J. van den Bent, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 7, pp. 395-407
Closed Access | Times Cited: 23
Systematic Review of Cerebrospinal Fluid Biomarker Discovery in Neuro-Oncology: A Roadmap to Standardization and Clinical Application
Nicholas Mikolajewicz, Patricia Yee, Debarati Bhanja, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 16, pp. 1961-1974
Closed Access | Times Cited: 10
The genomic alterations in glioblastoma influence the levels of CSF metabolites
Daniel H. Wang, Yoko Fujita, Antonio Dono, et al.
Acta Neuropathologica Communications (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 8
Clinical applications of cerebrospinal fluid liquid biopsies in central nervous system tumors
María Díaz, Sofia Chudsky, Elena Pentsova, et al.
Translational Oncology (2024) Vol. 41, pp. 101881-101881
Open Access | Times Cited: 6
Biomarkers in Cerebrospinal Fluid for the Diagnosis and Monitoring of Gliomas
Dimosthenis Papadimitrakis, Miltiadis Perdikakis, Antonios N. Gargalionis, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 801-801
Open Access | Times Cited: 5
ctDNA detection in cerebrospinal fluid and plasma and mutational concordance with the primary tumor in a multicenter prospective study of patients with glioma
Santiago Cabezas-Camarero, Rebeca Pérez‐Alfayate, Vanesa Garcı́a, et al.
Annals of Oncology (2025)
Closed Access
A genetically encoded fluorescent sensor enables sensitive and specific detection of IDH mutant associated oncometabolite D-2-hydroxyglutarate
Kristian A. Choate, Wren Konickson, Zoe Moreno, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas
Cécile Riviere-Cazaux, Jean M. Lacey, Lucas P. Carlstrom, et al.
Neuro-Oncology Advances (2023) Vol. 5, Iss. 1
Open Access | Times Cited: 9
Extent of Resection Thresholds in Molecular Subgroups of Newly Diagnosed Isocitrate Dehydrogenase–Wildtype Glioblastoma
Antonio Dono, Ping Zhu, Takeshi Takayasu, et al.
Neurosurgery (2024) Vol. 95, Iss. 4, pp. 932-940
Closed Access | Times Cited: 3
Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomas
Syeda Maheen Batool, A. Escobedo, Tiffaney Hsia, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Imaging and Liquid Biopsy for Distinguishing True Progression From Pseudoprogression in Gliomas, Current Advances and Challenges
Kaishu Li, Qihui Zhu, Junyi Yang, et al.
Academic Radiology (2024) Vol. 31, Iss. 8, pp. 3366-3383
Open Access | Times Cited: 2
The dynamic impact of location and resection on the glioma CSF proteome
Cécile Riviere-Cazaux, Christopher Graser, Arthur E. Warrington, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Blood and cerebrospinal fluid biomarkers in neuro-oncology
Roberta Rudà, Alessia Pellerino, Riccardo Soffietti
Current Opinion in Neurology (2024)
Closed Access | Times Cited: 2
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma
Macarena I. de la Fuente, Mehdi Touat, Martin J. van den Bent, et al.
Neuro-Oncology (2024)
Closed Access | Times Cited: 2
Rapid detection of mutations in CSF-cfTNA with the Genexus Integrated Sequencer
Srividya Arjuna, Mauli Shah, Antonio Dono, et al.
Journal of Neuro-Oncology (2023) Vol. 166, Iss. 1, pp. 39-49
Closed Access | Times Cited: 5
Detection of IDH1 Mutation in cfDNA and Tissue of Adult Diffuse Glioma with Allele-Specific qPCR
Adil Husain, Sridhar Mishra, Mohammed Wasim Siddiqui, et al.
Asian Pacific Journal of Cancer Prevention (2023) Vol. 24, Iss. 3, pp. 961-968
Open Access | Times Cited: 4
IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications
Kristian A. Choate, Evan P.S. Pratt, Matthew J. Jennings, et al.
Biology (2024) Vol. 13, Iss. 11, pp. 885-885
Open Access
Who will benefit from vorasidenib? Review of data from the literature and open questions
Amélie Darlix, Matthias Preusser, Shawn L. Hervey‐Jumper, et al.
Neuro-Oncology Practice (2024) Vol. 12, Iss. Supplement_1, pp. i6-i18
Open Access
Application of Circulating Tumor DNA in the Auxiliary Diagnosis and Prognosis Prediction of Glioma
Ying Lu, Zhouyu Wang, Danmeng Zhang, et al.
Cellular and Molecular Neurobiology (2024) Vol. 45, Iss. 1
Open Access
A field resource for the glioma cerebrospinal fluid proteome: impacts of resection and location on biomarker discovery
Cécile Riviere-Cazaux, Christopher Graser, Arthur E. Warrington, et al.
Neuro-Oncology (2024)
Closed Access
Cerebrospinal fluid 2-hydroxyglutarate (2-HG) as a monitoring biomarker for IDH-mutant gliomas
Cécile Riviere-Cazaux, Jean M. Lacey, Lucas P. Carlstrom, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
A systematic review of CSF biomarker discovery in neuro-oncology: A roadmap to standardization and clinical application
Nicholas Mikolajewicz, Patricia Yee, Debarati Bhanja, et al.
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top